Bristol Myers Squibb (BMY) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the ...

Share price of Bristol Myers Squibb (BMY) touched a 52-week low of $42.96 on July 31, post its second-quarter earnings release. The stock has recovered 6.7% since then and is currently trading at ...

If you are wondering whether Bristol-Myers Squibb is attractively priced right now, this article will walk through what the current share price could mean for long term investors. The stock last ...

At first glance, Bristol-Myers Squibb appears cheap with a low P/E and strong dividend yield. GAAP earnings are consistently much lower than non-GAAP figures, reflecting costs which may limit cash ...

As the Q4 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the ...

Bristol-Myers Squibb Company (NYSE:BMY) is one of the Best Beaten Down Stocks to Buy According to Hedge Funds. On October 10, Citi lifted the price target on the company’s stock to $48 from $47, while ...

Investors in Bristol Myers Squibb Co. (Symbol: BMY) saw new options begin trading today, for the December 26th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ...

Bristol Myers Squibb & Co. (NYSE:BMY) on Tuesday announced results from the Phase 3 EXCALIBER-RRMM study evaluating iberdomide, an investigational cereblon E3 ligase modulator (CELMoD), combined with ...

Bristol Myers BMY is banking on its growth portfolio, which comprises Opdivo, Orencia, Yervoy, Reblozyl, Opdualag, Abecma, Zeposia, Breyanzi, Camzyos, Sotyku, Krazati and others, to drive top-line ...